Clinical Trials Logo

Germline BRCA2 Gene Mutation clinical trials

View clinical trials related to Germline BRCA2 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT04983628 Active, not recruiting - Clinical trials for Prostate Cancer Metastatic

Molecular Profiling in Prostate Cancer

ProProstate
Start date: October 1, 2020
Phase:
Study type: Observational

We aim to employ targeted DNA NGS to evaluate the prevalence of germline and somatic mutations in cancer predisposing genes, such as BRCA1 and BRCA2, and other HR and DDR genes, including also a few additional clinically relevant genes, in patients with metastatic, locally advanced or high-grade prostate cancer. In addition, we will investigate the prognostic role of these mutations as well as their association with various clinicopathological parameters. This will be the first study investigating the prevalence of germline and somatic pathogenic mutations in Greek patients with prostate cancer.

NCT ID: NCT04668521 Terminated - Adnexal Mass Clinical Trials

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

OVA360
Start date: May 4, 2020
Phase:
Study type: Observational

The objective of this project is to validate a next-generation assay that utilizes both the protein biomarkers of our already established ovarian cancer risk assessment combined with a molecular profile in both germline and early somatic detection.

NCT ID: NCT04585074 Recruiting - Breast Neoplasms Clinical Trials

Prospective Study of MAstectomy With Reconstruction Including Robot Endoscopic Surgery

MARRES
Start date: April 8, 2020
Phase:
Study type: Observational

Robotic mastectomy and immediate reconstruction have been introduced in 2015. However, since robotic mastectomy is the latest surgical technique, there is a lack of studies prospectively comparing conventional mastectomy and immediate reconstruction with robotic mastectomy. For this reason, this study is designed to establish a single institution cohort study that prospectively collects patients undergoing mastectomy and reconstruction. This study was initially designed as a single institution study, however, currently, the study was extended to the multicenter study including 18 institutions over the country. Using the established prospective cohort data, a comparative study of robotic mastectomy with conventional mastectomy and reconstruction, and cost-effectiveness and satisfaction of robotic endoscopic surgery, and cost-effectiveness and satisfaction of reconstructive surgery are to be analyzed.

NCT ID: NCT04584255 Recruiting - Breast Cancer Clinical Trials

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Start date: December 18, 2020
Phase: Phase 2
Study type: Interventional

This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: - Niraparib (Zejula) - Dostarlimab

NCT ID: NCT04090567 Recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Start date: July 28, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well olaparib with cediranib or AZD6738 works in treating patients with germline BRCA mutated breast cancer that has spread to other places in the body (advanced or metastatic). Olaparib, cediranib, and AZD6738 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.